Skye Bioscience, Inc. (SKYE)

12.69 -0.31 (-2.42%) As of 02:23PM EDT. Market open.

Skye Bioscience, Inc.

11250 El Camino Real
Suite 100
San Diego, CA 92130
United States
858 410 0266
https://skyebioscience.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 11

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Punit S. Dhillon B.A.	Executive Chairman, President, CEO & Secretary	720k	N/A	1980
Ms. Kaitlyn Melanie Arsenault CPA	Chief Financial Officer	476k	N/A	1987
Dr. Christopher G. Twitty Ph.D.	Chief Scientific Officer	N/A	N/A	1973
Mr. Tu Diep M.Sc.	Chief Development Officer	N/A	N/A	1981

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Corporate Governance

Skye Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.